RY 172.54 -0.45% SHOP 154.05 0.6929% TD 76.45 -0.1045% ENB 61.59 0.9507% BN 82.38 -0.2905% TRI 232.15 0.5762% CNQ 45.12 1.6674% CP 106.18 2.0177% CNR 147.02 0.7193% BMO 139.7 0.1075% BNS 77.12 -0.0907% CSU 4453.8501 0.2011% CM 90.52 -0.4509% MFC 44.04 -0.2717% ATD 79.0 -0.9032% NGT 55.77 4.204% TRP 67.89 1.3435% SU 52.035 1.413% WCN 246.9 0.1217% L 190.01 0.444%
Last update at 2025-01-02T17:31:00Z
18 Best 52-Week Low Stocks To Buy Now
Sat 27 Jan 24, 10:29 AMAre Medical Stocks Lagging Adicet Bio (ACET) This Year?
Tue 09 Jan 24, 09:49 PM12 Most Profitable Pot Stocks Now
Wed 27 Dec 23, 11:37 PMAurora Cannabis Inc. (TSE:ACB) Is Expected To Breakeven In The Near Future
Tue 12 Dec 23, 11:06 AMCould Aurora Cannabis Be a Screaming Buy Right Now?
Sun 10 Dec 23, 01:08 PMIs Aurora Cannabis Stock a Buy Now?
Wed 06 Dec 23, 01:42 PMDown 99.5%, Is Now the Time to Buy Aurora Cannabis?
Wed 06 Dec 23, 10:52 AMWeekly Roundup on the Cannabis Sector & Psychedelic Sector
Mon 08 Aug 22, 11:00 AM| Breakdown | 2024-03-31 | 2023-06-30 | 2023-03-31 | 2022-06-30 | 2022-03-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2024-03-31 | 2023-06-30 | 2023-03-31 | 2022-06-30 | 2022-03-31 |
| Income before tax | -59.59900M | -221.53200M | -264.54867M | -1720.12000M | -1720.12000M |
| Minority interest | - | - | 2.06M | 0.35M | 0.35M |
| Net income | -69.32600M | -198.99700M | -263.78601M | -1717.97900M | -1717.62400M |
| Selling general administrative | 104.94M | 133.40M | 68.22M | 126.97M | 126.97M |
| Selling and marketing expenses | 51.94M | - | 51.97M | 62.02M | 62.02M |
| Gross profit | 131.46M | -33.35400M | -60.44518M | 21.23M | 21.23M |
| Reconciled depreciation | 33.07M | - | 65.23M | 93.66M | 93.66M |
| Ebit | -12.59700M | - | -245.49672M | -219.37500M | -236.74900M |
| Ebitda | 20.47M | - | -203.31683M | -143.08900M | -143.08900M |
| Depreciation and amortization | 33.07M | - | 42.18M | 76.29M | 93.66M |
| Non operating income net other | - | - | - | - | - |
| Operating income | -46.45300M | -220.67800M | -245.49672M | -219.37500M | -231.44900M |
| Other operating expenses | 297.36M | - | 477.08M | 440.71M | 440.71M |
| Interest expense | 14.19M | - | 39.46M | 71.81M | 71.81M |
| Tax provision | -0.55400M | -15.23700M | -15.23700M | -2.14100M | -2.14100M |
| Interest income | 12.81M | 2.53M | 2.53M | 4.51M | 4.51M |
| Net interest income | -1.37300M | - | -51.52500M | -67.30600M | -67.30600M |
| Extraordinary items | - | - | - | 0.00000M | 0.00000M |
| Non recurring | - | - | - | - | - |
| Other items | - | - | - | - | - |
| Income tax expense | -0.55400M | - | -20.24528M | -2.14100M | -2.14100M |
| Total revenue | 270.28M | 174.97M | 231.58M | 221.34M | 221.34M |
| Total operating expenses | 158.54M | - | 185.05M | 240.60M | 240.60M |
| Cost of revenue | 138.82M | 208.32M | 292.03M | 200.11M | 200.11M |
| Total other income expense net | -31.14700M | - | -19.05195M | -1500.74500M | -1433.43900M |
| Discontinued operations | - | - | - | - | - |
| Net income from continuing ops | -59.04500M | - | -1750.02200M | -1717.97900M | -1717.97900M |
| Net income applicable to common shares | - | -198.99700M | -198.99700M | -1717.62400M | -1717.62400M |
| Preferred stock and other adjustments | - | - | - | - | - |
| Breakdown | 2024-03-31 | 2023-06-30 | 2023-03-31 | 2022-06-30 | 2022-03-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2024-03-31 | 2023-06-30 | 2023-03-31 | 2022-06-30 | 2022-03-31 |
| Total assets | 838.67M | 926.32M | 926.32M | 1084.36M | 1084.36M |
| Intangible assets | 40.85M | 59.68M | 61.40M | 70.70M | 70.70M |
| Earning assets | - | - | - | - | - |
| Other current assets | 9.40M | 66.54M | 8.92M | 119.01M | 6.54M |
| Total liab | 236.80M | 440.25M | 404.62M | 422.00M | 422.00M |
| Total stockholder equity | 559.77M | 486.08M | 490.64M | 661.84M | 661.84M |
| Deferred long term liab | - | - | - | - | - |
| Other current liab | 45.39M | - | 66.50M | 94.52M | 94.52M |
| Common stock | 6971.42M | 6841.23M | 6841.23M | 6754.63M | 6754.63M |
| Capital stock | 6971.42M | - | - | 6754.63M | 6754.63M |
| Retained earnings | -6367.93600M | -6056.41200M | -6292.26500M | -6038.27500M | -6038.27500M |
| Other liab | - | - | - | 40.29M | 40.29M |
| Good will | 43.18M | 18.71M | 18.71M | 0.00000M | 0.00000M |
| Other assets | - | 38.53M | 38.53M | 33.87M | 33.87M |
| Cash | 113.44M | - | 300.84M | 437.81M | 437.81M |
| Cash and equivalents | - | 234.94M | 234.94M | 437.81M | 437.81M |
| Total current liabilities | 124.62M | 242.31M | 237.74M | 145.23M | 145.23M |
| Current deferred revenue | 1.69M | - | 1.74M | 3.85M | 3.85M |
| Net debt | -8.64800M | - | -73.32000M | -168.31600M | -168.31600M |
| Short term debt | 57.22M | 0.00000M | 147.56M | 33.00M | 33.00M |
| Short long term debt | 52.36M | - | - | 26.85M | 26.85M |
| Short long term debt total | 104.79M | - | 227.52M | 269.49M | 269.49M |
| Other stockholder equity | - | -298.74600M | -0.00000M | -54.50800M | -54.50800M |
| Property plant equipment | - | 322.97M | 322.97M | 230.30M | 230.30M |
| Total current assets | 426.61M | 479.93M | 479.93M | 745.12M | 745.12M |
| Long term investments | - | - | - | 1.21M | 1.21M |
| Net tangible assets | - | - | - | 587.99M | 587.99M |
| Short term investments | 4.04M | 0.00000M | 0.00000M | 1.33M | 1.33M |
| Net receivables | 45.41M | 35.02M | 41.34M | 47.05M | 47.05M |
| Long term debt | 4.90M | 36.16M | 36.16M | 199.65M | 199.65M |
| Inventory | 186.38M | 128.82M | 128.82M | 139.93M | 139.93M |
| Accounts payable | 20.32M | - | 21.94M | 13.86M | 13.86M |
| Total permanent equity | - | - | - | - | - |
| Noncontrolling interest in consolidated entity | - | - | - | - | - |
| Temporary equity redeemable noncontrolling interests | - | - | - | - | - |
| Accumulated other comprehensive income | -43.70700M | - | -58.32500M | -54.50800M | -54.50800M |
| Additional paid in capital | - | - | - | - | - |
| Common stock total equity | - | - | - | - | - |
| Preferred stock total equity | - | - | - | - | - |
| Retained earnings total equity | - | - | - | - | - |
| Treasury stock | - | - | - | - | - |
| Accumulated amortization | - | - | - | - | - |
| Non currrent assets other | 12.03M | - | 14.06M | 33.87M | -305.36800M |
| Deferred long term asset charges | - | - | - | - | - |
| Non current assets total | 412.07M | - | 446.39M | 339.24M | 339.24M |
| Capital lease obligations | 47.53M | - | - | 42.99M | 42.99M |
| Long term debt total | - | 79.97M | 79.97M | 236.49M | 236.49M |
| Breakdown | 2024-03-31 | 2023-06-30 | 2023-03-31 | 2022-06-30 | 2022-03-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2024-03-31 | 2023-06-30 | 2023-03-31 | 2022-06-30 | 2022-03-31 |
| Investments | -5.48700M | - | -54.67400M | -36.60000M | -36.60000M |
| Change to liabilities | - | - | - | 3.31M | 3.31M |
| Total cashflows from investing activities | - | -27.29100M | -27.29100M | -36.60000M | -36.60000M |
| Net borrowings | - | - | - | -170.83100M | -170.83100M |
| Total cash from financing activities | -47.92300M | -71.40600M | -56.47800M | 147.78M | 147.78M |
| Change to operating activities | - | - | - | 6.47M | 6.47M |
| Net income | -59.04500M | -206.29500M | -234.57275M | -1717.97900M | -1717.97900M |
| Change in cash | -121.50300M | -202.86500M | -140.00900M | 16.35M | 16.35M |
| Begin period cash flow | 234.94M | 437.81M | 440.85M | 421.46M | 421.46M |
| End period cash flow | 113.44M | - | 300.84M | 437.81M | 437.81M |
| Total cash from operating activities | -68.50800M | -115.82100M | -115.80500M | -109.83800M | -109.83800M |
| Issuance of capital stock | 37.93M | - | 417.75M | 350.19M | 350.19M |
| Depreciation | 33.07M | 31.99M | 42.18M | 93.66M | 93.66M |
| Other cashflows from investing activities | - | -15.15900M | -15.15900M | -0.18500M | -0.18500M |
| Dividends paid | - | - | - | - | - |
| Change to inventory | 3.62M | - | 49.51M | 21.07M | 21.07M |
| Change to account receivables | -4.33300M | - | 2.97M | 18.76M | 18.76M |
| Sale purchase of stock | - | 73.19M | 73.19M | 350.19M | 350.19M |
| Other cashflows from financing activities | -0.08900M | -14.92800M | -0.12300M | -31.57800M | -31.57800M |
| Change to netincome | - | - | - | 1464.18M | 1464.18M |
| Capital expenditures | 16.96M | 12.13M | 9.33M | 32.21M | 32.21M |
| Change receivables | - | - | - | - | - |
| Cash flows other operating | - | - | - | - | - |
| Exchange rate changes | - | - | - | - | - |
| Cash and cash equivalents changes | - | - | - | - | - |
| Change in working capital | -15.62700M | -25.11600M | -24.83600M | 49.95M | 49.95M |
| Stock based compensation | 12.72M | - | 16.89M | 13.76M | 13.76M |
| Other non cash items | -70.84100M | - | 159.74M | 1452.97M | 1452.97M |
| Free cash flow | -85.46400M | - | -125.13200M | -142.05100M | -142.05100M |
Sector: Healthcare Industry: Drug Manufacturers - Specialty & Generic
| Company | Change (CAD) | Price (CAD) | Trailing PE (x) | Forward PE (x) | Price Sales TTM (x) | Price to Book Value (x) | Enterprise Value to Revenue (x) | Enterprise Value to EBITDA (x) |
|---|---|---|---|---|---|---|---|---|
| ACB Aurora Cannabis Inc |
0.47 7.69% | 6.58 | - | - | 1.23 | 0.68 | 1.29 | 101.44 |
| BHC Bausch Health Companies Inc |
- -% | 11.62 | - | 2.23 | 0.50 | 18.74 | 2.56 | 9.13 |
| CURA Curaleaf Holdings Inc. |
0.10 4.46% | 2.34 | - | 138.89 | 1.62 | 1.66 | 1.73 | 10.18 |
| TLRY Tilray Inc |
0.20 10.53% | 2.10 | - | 1000.00 | 2.17 | 0.36 | 1.69 | -2.299 |
| CRON Cronos Group Inc |
0.05 1.73% | 2.94 | - | - | 10.18 | 0.70 | 0.02 | -1.9458 |
Aurora Cannabis Inc., together with its subsidiaries, engages in the production, distribution, and sale of cannabis and cannabis-derivative products in Canada and internationally. It operates through two segments, Canadian Cannabis and Plant Propagation. The company offers medical and consumer cannabis products; supplies propagated vegetables and ornamental plants; and distributes and sells hemp-derived cannabidiol (CBD) products. The company also cultivates and sells dried cannabis, cannabis oils, capsules, edible cannabis, cannabis extracts, and soft gels, which are ingested in various ways, including smoking, vaporizing, and consumption in the form of oil, capsules, dried flowers, vapes, dried milled strains, edibles, concentrates, and strain specific cannabis oils and extracts; and provides patient counseling and outreach services. Its adult-use brand portfolio includes Aurora Drift, San Rafael '71, Daily Special, Whistler, Being, and Greybeard, as well as CBD brands, Reliva and KG7; and medical cannabis brands include MedReleaf, CanniMed, Aurora, Whistler Medical Marijuana Co, Pedanios, Bidiol, and CraftPlant. The company was founded in 2013 and is headquartered in Edmonton, Canada.
90B Street SW, Edmonton, AB, Canada, T6X 1V8
| Name | Title | Year Born |
|---|---|---|
| Mr. Miguel Martin | CEO & Director | 1972 |
| Mr. Glen Ibbott | Chief Financial Officer | NA |
| Mr. Alex Miller | Exec. VP of Operations & Supply Chain | NA |
| Ms. Lori Schick | Exec. VP of HR | NA |
| Mr. Andre Jerome | Exec. VP of Global Bus. Devel. | NA |
| Ananth Krishnan | VP of Capital Markets & Investor Relations | NA |
| Mr. Nathalie Clark | Exec. VP, Gen. Counsel & Corp. Sec. | NA |
| Michelle Lefler | VP of Communications & PR | NA |
| Mr. Carey Squires | Exec. VP of Corp. Devel. & Strategy | NA |
| Mr. John Barnet | Chief Cultivator | NA |
Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on ‘as is’ basis, using their API. The information and data provided on this page, as well as via the API, are not guaranteed to be real-time or accurate. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general informational purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine does not assume any responsibility for any trading losses you might incur as a result of using this information, data, or any analyst rating or recommendation provided. Kalkine will not accept any liability for any loss or damage resulting from reliance on the information, including but not limited to data, quotes, charts, analyst ratings, recommendations, and buy/sell signals sourced via the API.
Please be fully informed about the risks and costs associated with trading in the financial markets, as it is one of the riskiest forms of investment. Kalkine does not provide any warranties regarding the information on this page, including, without limitation, warranties of merchantability or fitness for a particular purpose or use.
CA 
AU
UK
US
NZ
Please wait processing your request...